
microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

AMR: Partnership set to improve in vivo antibiotics testing
The development of novel antibiotics is crucial in the fight against antimicrobial resistance (AMR) but has been neglected for decades due to a lack...

Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie has become the latest big pharma company to target the hot antibody-drug conjugate market, acquiring ImmunoGen and its Elahere ADC for...

CPHI: Trends shaping pharma's path
Despite challenges such as funding slowdowns for biotechs and concerns about high inflation, the industry remains cautiously optimistic,...

UK publishes £2bn vision for engineering biology
Following extensive engagement with industry and stakeholders, the new "National Vision for Engineering Biology" lays out the government’s...

Synerkine Pharma BV secures EUR 12.1m in Series A extension
The Series A extension was led by Flerie with participation of existing investor Thuja Capital and new investors InnovationQuarter Capital and...

Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...